정규장
Log in Sign up
🏛️
거래 정지 중인 종목 2026-07-20 이후 거래가 정지되었습니다. 재개될 수 있으며, 표시된 시세는 마지막 거래일 기준입니다.
ADTX
ADTX
Aditxt Inc
7월 28일 2:23 PM ET (한국 7/29 03:23)
$0.01
+0.00 +0.00%

아디텍스트(ADTX) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$9M
스몰캡
P/E
-
배당수익률
없음
52주 위치
-
고점 -100%
애널리스트
-
A+
Fundamental health
vs. 방어주 초소형주· based on 1 axes
수익성
데이터 부족
성장
Top 1%
밸류에이션
데이터 부족
재무 안정
데이터 부족
Index -P/E -EPS (ttm) -1380.8Insider Own 0.03%Shs Outstand 998.0MPerf Week -
Market Cap 0.01BForward P/E -EPS next Y -Insider Trans -84.45%Shs Float 0.4MPerf Month -80.96%
Enterprise Value -PEG -EPS next Q -Inst Own -Short Float 69.72%Perf Quarter -99.93%
Income -P/S 661.33EPS this Y -Inst Trans -Short Ratio 0Perf Half Y -100%
Sales 0.00BP/B -EPS next 5Y -ROA -Short Interest 0.28MPerf YTD -99.99%
Book/sh -861.43P/C -EPS past 3/5Y 99.4% -ROE -52W High -100% Perf Year -100%
Cash/sh -P/FCF -Sales past 3/5Y -84.93% -ROIC -52W Low -Perf 3Y -100%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 99.99%Gross Margin -Volatility(W/M) 219.76% 88.22%Perf 5Y -100%
Dividend TTM -EV/Sales -Sales Y/Y TTM -74.09%Oper. Margin -ATR (14) 0.35Perf 10Y -
Dividend Ex-Date -Quick Ratio -EPS Q/Q -Profit Margin -RSI (14) 13.65Recom -
Dividend Gr. 3/5Y -Current Ratio -Sales Q/Q 1094.4%SMA20 -83.82% ($0.06)Beta 0.89Target Price -
Payout -Debt/Eq -Earnings -SMA50 -99.69% ($3.23)Rel Volume 0Prev Close $0.01
Employees 26LT Debt/Eq -EPS/Sales Surpr. - 120.59%SMA200 -100% Avg Volume(3M) 380.86MPrice $0.01
IPO 2020/6/30Option/Short No/YesTrades 0Volume -Change -
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Aditxt Inc (ADTX) Investment Analysis

What kind of company is Aditxt Inc?

아디텍스트(ADTX) 방어주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

🧬 A biotechnology company that develops and commercializes innovative biotechnology in the fields of immune health, precision medicine, and population health. Founded in 2017, Aditxt (ADTX) has a product portfolio leveraging immune profiling analysis, apoptosis-based immunotherapy, and diagnostic technology for mitochondrial genetic disorders.

Learn more about Aditxt Inc →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5529
Employees26people
IPO2020/06/30
Current Price$0.01 ≈ 14원
NASD · USA

Key Events

예정된 이벤트가 없습니다

ADTX의 다음 실적 발표일이나 배당 일정이 아직 수집되지 않았습니다.

  • 실적 발표는 보통 분기마다 있습니다
  • 배당주는 연 1~4회 배당락일이 있습니다
전체 경제/실적 캘린더 보기 →

Is it profitable?

Financial metrics unavailable

Profitability and financial-health indicators have not yet been collected.

What's the outlook?

Outlook data is insufficient

Analyst estimates and price targets have not been collected.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth
Mid-range within the industry
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+99.4%
우수
My positionTop 5%
Low range Average High range
방어주 초소형주 Median 30.0% · Top tier
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
+1094.4%
우수
My positionTop 5%
Low range Average High range
방어주 초소형주 Median -4.5% · Top tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -168%p below the market
ADTX -100.0% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-168.3%p
Significantly behind the market
vs Health Care (XLV)
-124.5%p
Significantly behind the sector average
1-year basis
vs S&P 500
-116.0%p
Significantly behind the market
vs Health Care (XLV)
-119.7%p
Significantly behind the sector average
Rank among peers
5-year return Lowest among peers Based on 245 peers
1-year return Lowest among peers Based on 315 peers
Recent risk (last 116 trading days)
Max drawdown
-99.7%
Annualized volatility
684.2%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 69-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-10
Downtrend zone

Current price $0.01 below the midline ($0.01). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡
Current diagnosis · 2026-07-10
Neutral zone — weak trend

MACD -0.053 · Signal -0.068 · Hist 0.015. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴
Current diagnosis · 2026-07-10
Bearish zone

RSI 38.7 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 0.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🧾 Vs. Sales Pricey
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
661.33x
✓ Very pricey
My positionBottom 5%
Low range Average High range
Biotechnology 초소형주 median 11.24x · Bottom 1% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership backdrop is unfavorable
Insider net selling -84.5% · Short interest very high 69.7% · Short interest up +62.5pp over last 88d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
-84.5%
Insiders large net selling
🏦 Institutions (funds & investors)
-
No trading data for Institutions
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🧑‍💼 Insiders 0.0%
Low, common among large-caps
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 100.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
69.7%
Very high — strong short-side pressure
전체 시장 Median -%
Past 88 days 📈 +62.5%p increase
Short interest days to cover
0.0 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 998.0M주
Float (tradable shares) 0.4M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 88 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
ADTX ADTX This Stock
$9.5M- - - - +0.0%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen
시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.